[{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","sponsor":"European Union","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Profil Institut f\u00fcr Stoffwechselforschung GmbH \/ European Union","highestDevelopmentStatusID":"6","companyTruncated":"Profil Institut f\u00fcr Stoffwechselforschung GmbH \/ European Union"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Tetris Pharma","sponsor":"Arecor","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tetris Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tetris Pharma \/ Arecor","highestDevelopmentStatusID":"15","companyTruncated":"Tetris Pharma \/ Arecor"},{"orgOrder":0,"company":"Tetris Pharma","sponsor":"Arecor","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tetris Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tetris Pharma \/ Arecor","highestDevelopmentStatusID":"15","companyTruncated":"Tetris Pharma \/ Arecor"},{"orgOrder":0,"company":"Stanford University","sponsor":"University of Virginia | DexCom | Helmsley Charitable Trust","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ University of Virginia | DexCom | Helmsley Charitable Trust","highestDevelopmentStatusID":"1","companyTruncated":"Stanford University \/ University of Virginia | DexCom | Helmsley Charitable Trust"},{"orgOrder":0,"company":"Yale University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Yale University \/ Merck & Co"},{"orgOrder":0,"company":"Jaeb Center for Health Research","sponsor":"Xeris Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Jaeb Center for Health Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jaeb Center for Health Research \/ Xeris Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Jaeb Center for Health Research \/ Xeris Pharmaceuticals"},{"orgOrder":0,"company":"Jaeb Center for Health Research","sponsor":"Xeris Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Jaeb Center for Health Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jaeb Center for Health Research \/ Xeris Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Jaeb Center for Health Research \/ Xeris Pharmaceuticals"},{"orgOrder":0,"company":"Clinique Ovo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Clinique Ovo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clinique Ovo \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Clinique Ovo \/ Undisclosed"},{"orgOrder":0,"company":"Joslin Diabetes Center","sponsor":"National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | Xeris Pharmaceuticals | Harvard University","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Joslin Diabetes Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Joslin Diabetes Center \/ National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | Xeris Pharmaceuticals | Harvard University","highestDevelopmentStatusID":"7","companyTruncated":"Joslin Diabetes Center \/ National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | Xeris Pharmaceuticals | Harvard University"},{"orgOrder":0,"company":"Oregon Health and Science University","sponsor":"Xeris Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Oregon Health and Science University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Oregon Health and Science University \/ Xeris Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Oregon Health and Science University \/ Xeris Pharmaceuticals"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"South Texas Veterans Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Texas Health Science Center at San Antonio \/ South Texas Veterans Health Care System","highestDevelopmentStatusID":"6","companyTruncated":"University of Texas Health Science Center at San Antonio \/ South Texas Veterans Health Care System"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | Emissary International","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xeris Pharmaceuticals \/ National Institute of Diabetes and Digestive and Kidney Diseases | Emissary International","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ National Institute of Diabetes and Digestive and Kidney Diseases | Emissary International"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xeris Pharmaceuticals \/ National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"SGS Life Sciences | Integrated Medical Development","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ SGS Life Sciences | Integrated Medical Development","highestDevelopmentStatusID":"10","companyTruncated":"Xeris Pharmaceuticals \/ SGS Life Sciences | Integrated Medical Development"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Empiristat","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Empiristat","highestDevelopmentStatusID":"10","companyTruncated":"Xeris Pharmaceuticals \/ Empiristat"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | Emissary International","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ National Institute of Diabetes and Digestive and Kidney Diseases | Emissary International","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ National Institute of Diabetes and Digestive and Kidney Diseases | Emissary International"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | Emissary International","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ National Institute of Diabetes and Digestive and Kidney Diseases | Emissary International","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ National Institute of Diabetes and Digestive and Kidney Diseases | Emissary International"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi USA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Fresenius Kabi USA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi USA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fresenius Kabi USA \/ Undisclosed"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xeris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AmideBio","sponsor":"NIDDK","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Funding","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AmideBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"AmideBio \/ NIDDK","highestDevelopmentStatusID":"4","companyTruncated":"AmideBio \/ NIDDK"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Beta Bionics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Beta Bionics","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Beta Bionics"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Megapharm","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Megapharm","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Megapharm"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Tetris Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Tetris Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Tetris Pharma"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Xeris Pharmaceuticals \/ The Emmes Company, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Xeris Pharmaceuticals \/ The Emmes Company, LLC"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Xeris Pharmaceuticals \/ National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"10","companyTruncated":"Xeris Pharmaceuticals \/ National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Integrated Medical Development","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Xeris Pharmaceuticals \/ Integrated Medical Development","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Integrated Medical Development"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Zosano Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zosano Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Locemia Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Eli Lilly \/ Locemia Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Locemia Solutions"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Private Placement","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amphastar Pharmaceuticals","amount2":0.29999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.29999999999999999,"dosageForm":"Powder","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amphastar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Divestment","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":1.0800000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":1.0800000000000001,"dosageForm":"Powder","sponsorNew":"Eli Lilly \/ Amphastar Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Amphastar Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amphastar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Divestment","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":1.0800000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":1.0800000000000001,"dosageForm":"Powder","sponsorNew":"Eli Lilly \/ Amphastar Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Amphastar Pharmaceuticals"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Xeris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xeris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Locemia Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Locemia Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Locemia Solutions"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"T1D Exchange Clinic Network Coordinating Center | Locemia Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ T1D Exchange Clinic Network Coordinating Center | Locemia Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ T1D Exchange Clinic Network Coordinating Center | Locemia Solutions"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Jaeb Center for Health Research | Locemia Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Jaeb Center for Health Research | Locemia Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Jaeb Center for Health Research | Locemia Solutions"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Locemia Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Locemia Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Locemia Solutions"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Locemia Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Locemia Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Locemia Solutions"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Locemia Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Locemia Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Locemia Solutions"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Locemia Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Locemia Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Locemia Solutions"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Locemia Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Locemia Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Locemia Solutions"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Abvance Therapeutics","sponsor":"T1D Exchange","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Abvance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abvance Therapeutics \/ T1D Exchange","highestDevelopmentStatusID":"6","companyTruncated":"Abvance Therapeutics \/ T1D Exchange"},{"orgOrder":0,"company":"Abvance Therapeutics","sponsor":"Helmsley Charitable Trust","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Financing","leadProduct":"Insulin","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Abvance Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abvance Therapeutics \/ Helmsley Charitable Trust","highestDevelopmentStatusID":"4","companyTruncated":"Abvance Therapeutics \/ Helmsley Charitable Trust"}]
Find Clinical Drug Pipeline Developments & Deals for Glucagon
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
